TG Therapeutics, Inc. (TGTX) News

TG Therapeutics, Inc. (TGTX): $12.81

0.32 (+2.56%)

POWR Rating

Component Grades

Momentum

D

Stability

F

Sentiment

Quality

B

Add TGTX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#32 of 342

in industry

Filter TGTX News Items

TGTX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

TGTX News Highlights

  • TGTX's 30 day story count now stands at 9.
  • Over the past 12 days, the trend for TGTX's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
  • The most mentioned tickers in articles about TGTX are TG and NOV.

Latest TGTX News From Around the Web

Below are the latest news stories about TG THERAPEUTICS INC that investors may wish to consider to help them evaluate TGTX as an investment opportunity.

Does TG Therapeutics (TGTX) Have the Potential to Rally 127.76% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 127.8% in TG Therapeutics (TGTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Yahoo | November 6, 2023

TG Therapeutics, Inc. (NASDAQ:TGTX) Q3 2023 Earnings Call Transcript

TG Therapeutics, Inc. (NASDAQ:TGTX) Q3 2023 Earnings Call Transcript November 5, 2023 Operator: Greetings, and welcome to the TG Therapeutics Third Quarter Earnings Update Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Jenna Bosco. Thank you, Jenna. You may begin. Jenna Bosco: Thank […]

Yahoo | November 6, 2023

TG Therapeutics to Participate in the 5th Annual Guggenheim Inflammation, Neurology & Immunology (INI) Conference

Fireside chat scheduled for Monday, November 6, 2023, at 3:10 PM ETNEW YORK, Nov. 03, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the 5th Annual Guggenheim Inflammation, Neurology & Immunology (INI) Conference, being held at the JW Marriott Essex House, in New York City on November 6 -7, 2023. The fireside chat is scheduled to take place on Monday, November 6, 2023, at

Yahoo | November 3, 2023

Why TG Therapeutics Stock Is Crushing It Today

Shares of the biopharmaceutical company were soaring 36.4% higher as of 11:32 a.m. ET. Why were TG Therapeutics' Q3 results so good? CEO Michael Weiss said in the company's press release announcing its Q3 results that the sales figure for Briumvi "again exceeded our expectations."

Yahoo | November 1, 2023

Morning Brew: AMD's Q4 Guidance Weighs on Stock, Apple's Negative Sentiment Overcooked, and Fed

Advanced Micro Devices (NASDAQ:AMD) stock was among the most actively traded ahead of the opening bell, with shares down marginally. Wedbush Securities has a positive outlook on both Apple's (NASDAQ:AAPL) iPhone and services segments ahead of the companys fourth-quarter earnings report on Thursday. The research firm believes that the overall sentiment of Apple on the Street is a negative groupthink mentality, which is very disconnected from the current iPhone 15 growth.

Yahoo | November 1, 2023

TG Therapeutics Inc (TGTX) Reports Third Quarter 2023 Financial Results

TG Therapeutics Inc (NASDAQ:TGTX) reported a total net revenue of $165.8 million for Q3 2023, including BRIUMVI net sales of $25.1 million in the United States. The company has seen approximately 2,200 BRIUMVI prescriptions since its launch from over 500 healthcare providers across approximately 350 centers in the U.S. Payor coverage is in place for approximately 95% of covered lives for BRIUMVI.

Yahoo | November 1, 2023

TG Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

Third quarter 2023 total net revenue of $165.8 million, including quarterly BRIUMVI® net sales of $25.1 million in the United States, and license revenue of $140.0 million from the upfront payment received from Neuraxpharm Approximately 2,200 BRIUMVI prescriptions since launch from 500+ healthcare providers at approximately 350 centers across the U.S. Payor coverage in place for approximately 95% of covered lives for BRIUMVI Conference call to be held today, November 1, 2023, at 8:30 AM ET NEW Y

Yahoo | November 1, 2023

TG Therapeutics to Host Conference Call on Third Quarter 2023 Financial Results and Business Update

Conference call to be held Wednesday, November 1, 2023, at 8:30 AM ETNEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Wednesday, November 1, 2023, at 8:30 AM ET to discuss results for the third quarter 2023 and provide a business outlook for remainder of the year. Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics, will host the call. In order to participate in the conference call, plea

Yahoo | October 30, 2023

TG Therapeutics, Inc. (NASDAQ:TGTX) Is Expected To Breakeven In The Near Future

With the business potentially at an important milestone, we thought we'd take a closer look at TG Therapeutics, Inc.'s...

Yahoo | October 25, 2023

13 Stocks to Buy with Exponential Growth

In this article, we will take a look at the 13 stocks to buy with exponential growth. To see more such companies, go directly to 5 Stocks to Buy with Exponential Growth. Optimism was prevailing in the US stock market on October 11 as investors were hopeful that the Federal Reserve won’t take a hawkish […]

Yahoo | October 14, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!